COMMUNIQUÉS West-GlobeNewswire

AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS
24/02/2026
PRESS RELEASE AB SCIENCE ANNOUNCES THE IDENTIFICATION OF A PLASMA BIOMARKER THAT INDICATES THE ACTIVITY OF MASITINIB IN TREATING AMYOTROPHIC LATERAL SCLEROSIS, AND THAT IS CAPABLE OF IDENTIFYING PATIENTS WITH PRO [...]
Empathy in Medicine Initiative Announces Student Chapter Program to Empower High School and College Students in Healthcare Leadership
24/02/2026
EMI launches Student Chapter Program to support students in starting empathy-focused healthcare clubs and community projects Empathy in Medicine Initiative (EMI) Image NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- The [...]
Research in carrot and cherry crops to strengthen local food security
24/02/2026
VANCOUVER, British Columbia, Feb. 24, 2026 (GLOBE NEWSWIRE) -- As climate change continues to disrupt Canada’s agricultural stability, Genome British Columbia (Genome BC) is funding two research collaborations to [...]
Linnaeus Therapeutics Awarded Up to $22 Million from ARPA-H to Advance LNS8801 for Healthspan Preservation
24/02/2026
ARPA-H PROSPR program to support accelerated development of LNS8801 to promote healthy aging HADDONFIELD, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Linnaeus Therapeutics, Inc., a privately held company focused on the [...]
AB Science annonce l'identification d'un biomarqueur plasmatique marqueur de l'activité du masitinib dans le traitement de la SLA
24/02/2026
COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE L'IDENTIFICATION D'UN BIOMARQUEUR PLASMATIQUE MARQUEUR DE L'ACTIVITÉ DU MASITINIB DANS LE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE, ET CAPABLE D'IDENTIFIER LES PATIENTS [...]
Surgery Partners, Inc. Announces Fourth Quarter 2025 Earnings Release Date and Conference Call Details
24/02/2026
BRENTWOOD, Tenn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will [...]
Validic Adds Epic Toolbox, Generative AI, Multi-Instance Support, and More to Existing Epic Integration
24/02/2026
New Epic-integrated features including Toolbox alignment, multi-instance support, AI-powered RPM summarization, and expanded wearable integrations help health systems ensure timely, risk-reducing care LOS ANGELES, Feb. [...]
Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board
24/02/2026
CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. [...]
Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests
24/02/2026
SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will present new data at the 2026 ASCO-GU conference supporting [...]
Respiree Strengthens Series A Syndicate to Advance Next-Generation Cardiorespiratory Care
24/02/2026
HOUSTON and SINGAPORE, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Respiree , a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum, today announced [...]
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement
24/02/2026
Company Highlights Advanced Partnering Discussions as AD04 Advances Toward Phase 3 GLEN ALLEN, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) (“Adial” or the “Company”), a clinical- [...]
Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments
24/02/2026
Max Homa shares his journey with seborrheic dermatitis to encourage others to take control of their symptoms ZORYVE ® (roflumilast) foam 0.3% is a once-daily, steroid-free, leave-in topical foam uniquely formulated to [...]
Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference
24/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its [...]
Communiqué de presse : Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique
24/02/2026
Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique Approbation chez les adultes et les enfants âgés de 6 ans et plus, appuyée par [...]
Dentsply Sirona and Burkhart Dental Supply Announce Expanded Distribution Partnership to Include Dental Technology Equipment
24/02/2026
As of April 1, Burkhart Dental Supply will represent Dentsply Sirona’s full portfolio of dental technology solutions in addition to preventive and restorative solutions it already distributes. The expanded partnership [...]
Human Continuum Appoints Dr. Michael Milligan, MD, MBA, as its Chief Medical Officer to Oversee Innovative Applications for Next-Generation Extracellular Vesicle Therapeutics
24/02/2026
New York, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Human Continuum Inc. (“HC” or “the Company”) , a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced that it has [...]
Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference
24/02/2026
Late-breaking presentation at MDA to feature Phase 3 HOPE-3 results supporting Deramiocel in Duchenne muscular dystrophy HOPE-3 clinical study report (CSR) submitted to the U.S. Food and Drug Administration (FDA) in [...]
Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study
24/02/2026
Results in a population of 278 patients affirm statistically significant mortality reductions Benefits observed across severity groups and in subjects with serious comorbidities Company files provisional patent [...]
Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
24/02/2026
CARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended December 31, 2025, before the [...]

Pages